华润双鹤(600062.SH)：公司药品新进国家医保目录

Core Viewpoint - China Resources Double Crane Pharmaceutical Co., Ltd. announced that its product, methylphenidate hydrochloride sustained-release capsules, has been included in the National Medical Insurance Directory for 2025, which will positively impact the company's market promotion and sales [1] Group 1: Product Information - The product included is methylphenidate hydrochloride sustained-release capsules, classified under code XN06B, used for treating Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 and above [1] - The inclusion in the National Medical Insurance Directory means that the product will be reimbursed under Category B during the agreement period [1] Group 2: Market Impact - The inclusion of the product in the National Medical Insurance Directory is expected to enhance market promotion and sales, leading to a positive impact on the company's operating performance [1] - The new National Medical Insurance Directory will officially take effect on January 1, 2026, and is not expected to have a significant impact on the company's performance for the current fiscal year [1]